Abstract PS14-01: Radium-223 in women with HR-positive bone-metastatic breast cancer receiving endocrine therapy: International phase 2, randomized, double-blind, placebo-controlled trial

Mapping Intimacies ◽

10.1158/1538-7445.sabcs20-ps14-01 ◽

2021 ◽

Author(s):

Robert E. Coleman ◽

Georgeta Fried ◽

Sung-Bae Kim ◽

Iryna Kuchuk ◽

David Kiesl ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Endocrine Therapy ◽

Controlled Trial ◽

Metastatic Breast ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy

10.1158/0008-5472.sabcs13-ot3-2-10 ◽

2013 ◽

Author(s):

N Turner ◽

F André ◽

S Loibl ◽

J Ro ◽

H Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive

Download Full-text

Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

10.1158/1538-7445.sabcs17-ot3-06-01 ◽

2018 ◽

Author(s):

PA Kaufman ◽

M Pipas ◽

GJ Finn ◽

SE Mathews ◽

H Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Systemic Therapy ◽

Metastatic Breast ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Hormone Receptor Positive ◽

Prior Systemic Therapy

Download Full-text

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00106-6 ◽

2016 ◽

Vol 17 (6) ◽

pp. 811-821 ◽

Author(s):

Ian E Krop ◽

Ingrid A Mayer ◽

Vinod Ganju ◽

Maura Dickler ◽

Stephen Johnston ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Oestrogen Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients (pts) with bone metastases (mets).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps1104 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS1104-TPS1104

Author(s):

Robert E. Coleman ◽

Liping Huang ◽

Oana Petrenciuc ◽

Paola Zaccarini

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases

10.1158/1538-7445.sabcs16-ot1-04-05 ◽

2017 ◽

Author(s):

HS Rugo ◽

KC Drumea ◽

M Campone ◽

A Barnadas ◽

O Petrenciuc ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive ◽

Positive Breast Cancer

Download Full-text

Abstract OT1-04-04: A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor–positive breast cancer patients with bone metastases

10.1158/1538-7445.sabcs16-ot1-04-04 ◽

2017 ◽

Author(s):

RE Coleman ◽

G Fried ◽

O Petrenciuc ◽

A Sawhney ◽

R Li ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Controlled Trial ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive ◽

Positive Breast Cancer

Download Full-text

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps621 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS621-TPS621 ◽

Author(s):

Hope S. Rugo ◽

Rui Li ◽

Oana Petrenciuc ◽

Amily Zhang ◽

Robert E. Coleman

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive ◽

Positive Breast Cancer

Download Full-text

A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients with bone metastases.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps622 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS622-TPS622

Author(s):

Robert E. Coleman ◽

Rui Li ◽

Amrita G. Sawhney ◽

Oana Petrenciuc ◽

Hope S. Rugo

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases

Annals of Oncology ◽

10.1093/annonc/mdw365.89 ◽

2016 ◽

Vol 27 ◽

pp. vi97 ◽

Author(s):

H. Rugo ◽

O. Petrenciuc ◽

A. Zhang ◽

R. Li ◽

R.E. Coleman

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive ◽

Positive Breast Cancer

Download Full-text

Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2‐Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study

The Oncologist ◽

10.1634/theoncologist.2012-0448 ◽

2013 ◽

Vol 18 (3) ◽

pp. 257-264 ◽

Author(s):

Sandra M. Swain ◽

Michael S. Ewer ◽

Javier Cortés ◽

Dino Amadori ◽

David Miles ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text